Cytokinetics, Inc.
Cytokinetics Announces Positive Results for Aficamten in HCM Treatment
Summary
Cytokinetics, Incorporated announced the primary results from the MAPLE-HCM trial, which demonstrated that the investigational drug aficamten significantly improved exercise capacity in patients with obstructive hypertrophic cardiomyopathy (oHCM) compared to metoprolol, a standard-of-care beta-blocker. The results were presented at the European Society of Cardiology Congress 2025 and published in The New England Journal of Medicine. Aficamten showed a statistically significant increase in peak oxygen uptake (pVO2) from baseline to Week 24, with a least-squares mean difference of 2.3 mL/kg/min (p<0.0001). The study also found that aficamten led to significant improvements in functional class and reduced patient symptom burden. Aficamten is currently under regulatory review in the U.S. for the treatment of symptomatic HCM.
Profitelligence Alerts
Get alerts for CYTK
Be first to know when Cytokinetics, Inc. files with the SEC.
Filing Categories
Advertisement
About Cytokinetics, Inc.
Cytokinetics, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of novel muscle activators as potential treatments for debilitating diseases. Primarily, the company's work aims to address unmet medical needs in the fields of neurology and cardiology, offering therapeutic solutions that target muscle function. Cytokinetics' research centers on small molecule drugs that modulate muscle performance, which could significantly aid patients suffering from heart failure, amyotrophic lateral sclerosis (ALS), and other muscle-related conditions. The company is actively involved in clinical trials and collaborates with other notable entities in its quest for innovative medical advancements. Its contributions to the healthcare sector exemplify the growing role of targeted therapy in improving patient outcomes. Headquartered in South San Francisco, California, Cytokinetics operates as a key player in the biotechnology landscape, with a commitment to pioneering treatments that leverage the complex mechanisms of muscle biology.
Official SEC Documents
Advertisement